Methylene Blue for Refractory Shock in Children: A Systematic Review and Survey Practice Analysis

Andrea V Otero Luna, Rachel Johnson, Melissa Funaro, Michael F Canarie, Richard W Pierce, Andrea V Otero Luna, Rachel Johnson, Melissa Funaro, Michael F Canarie, Richard W Pierce

Abstract

Objectives: Shock refractory to fluid and catecholamine therapy has significant morbidity and mortality in children. The use of methylene blue to treat refractory shock in children is not well described. We aim to collect and summarize the literature and define physicians' practice patterns regarding the use of methylene blue to treat shock in children.

Design: We conducted a systematic search of MEDLINE, Embase, PubMed, Web of Science, Cochrane for studies involving the use of methylene blue for catecholamine-refractory shock from database inception to 2019. Collected studies were analyzed qualitatively. To describe practice patterns of methylene blue use, we electronically distributed a survey to U.S.-based pediatric critical care physicians. We assessed physician knowledge and experience with methylene blue. Survey responses were quantitatively and qualitatively evaluated.

Setting: Pediatric critical and cardiac care units.

Patients or subjects: Patients less than or equal to 25 years old with refractory shock treated with methylene blue.

Interventions: None.

Measurements and main results: One-thousand two-hundred ninety-three abstracts met search criteria, 139 articles underwent full-text review, and 24 studies were included. Studies investigated refractory shock induced by a variety of etiologies and found that methylene blue was generally safe and increased mean arterial blood pressure. There is overall lack of studies, low number of study patients, and low quality of studies identified. Our survey had a 22.5% response rate, representing 125 institutions. Similar proportions of physicians reported using (40%) or never even considering (43%) methylene blue for shock. The most common reasons for not using methylene blue were unfamiliarity with this drug, its proper dosing, and lack of evidentiary support.

Conclusions: Methylene blue appears safe and may benefit children with refractory shock. There is a stark divide in familiarity and practice patterns regarding its use among physicians. Studies to formally assess safety and efficacy of methylene blue in treating pediatric shock are warranted.

Conflict of interest statement

Conflicts of Interest and Source of Funding: All authors have disclosed that they do not have any conflicts of interest.

Figures

Figure 1:
Figure 1:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart

References

    1. Carcillo JA, Kuch BA, Han YY, et al. Mortality and functional morbidity after use of PALS/APLS by community physicians. Pediatrics 2009;124(2):500–508.
    1. Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med 2015;191(10):1147–1157.
    1. Morin L, Ray S, Wilson C, et al. Refractory septic shock in children: a European Society of Paediatric and Neonatal Intensive Care definition. Intensive Care Med 2016;42(12):1948–1957.
    1. Ceneviva G, Paschall JA, Maffei F, et al. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998;102(2):e19.
    1. Deep A, Goonasekera CD, Wang Y, et al. Evolution of haemodynamics and outcome of fluid-refractory septic shock in children. Intensive Care Med 2013;39(9):1602–1609.
    1. Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017;45(6):1061–1093.
    1. Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017;377(5):419–430.
    1. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358(9):877–887.
    1. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 2018;378(9):809–818.
    1. Ouweneel DM, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive care medicine 2016;42(12):1922–1934.
    1. Masarwa R, Paret G, Perlman A, et al. Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis. Crit Care 2017;21(1):1.
    1. Yildizdas D, Yapicioglu H, Celik U, et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Med 2008;34(3):511–517.
    1. Yunge M, Petros A. Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child 2000;82(5):388–389.
    1. Lambden S, Creagh-Brown BC, Hunt J, et al. Definitions and pathophysiology of vasoplegic shock. Critical Care 2018;22(1):174.
    1. Lemson J, Nusmeier A, van der Hoeven JG. Advanced Hemodynamic Monitoring in Critically Ill Children. Pediatrics 2011;128(3):560.
    1. Gorelick MH, Shaw KN, Baker MD. Effect of ambient temperature on capillary refill in healthy children. Pediatrics 1993;92(5):699–702.
    1. Tibby SM, Hatherill M, Murdoch IA. Capillary refill and core-peripheral temperature gap as indicators of haemodynamic status in paediatric intensive care patients. Arch Dis Child 1999;80(2):163–166.
    1. Scott HF, Donoghue AJ, Gaieski DF, et al. Effectiveness of physical exam signs for early detection of critical illness in pediatric systemic inflammatory response syndrome. BMC Emerg Med 2014;14:24.
    1. Levitov A, Frankel HL, Blaivas M, et al. Guidelines for the Appropriate Use of Bedside General and Cardiac Ultrasonography in the Evaluation of Critically Ill Patients-Part II: Cardiac Ultrasonography. Crit Care Med 2016;44(6):1206–1227.
    1. Zhang X, Gao Y, Pan P, et al. [Methylene blue in the treatment of vasodilatory shock: a Meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2017;29(11):982–987.
    1. Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol 2010;26(4):517–520.
    1. Booth AT, Melmer PD, Tribble B, et al. Methylene Blue for Vasoplegic Syndrome. Heart Surg Forum 2017;20(5):E234–e238.
    1. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995;23(2):259–264.
    1. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77(2):496–499.
    1. Pasin L, Umbrello M, Greco T, et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc 2013;15(1):42–48.
    1. University Y. [cited Available from:
    1. Sun Y, Yi D, Wang Y, et al. Age-dependent mobilization of circulating endothelial progenitor cells in infants and young children undergoing cardiac surgery with cardiopulmonary bypass. Cytokine 2009;47(3):206–213.
    1. Chan BS, Becker T, Chiew AL, et al. Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome. J Med Toxicol 2018;14(1):100–103.
    1. Shen C, Shah N, Street J. Methylene Blue for Traumatic Vasoplegia. American Journal of Respiratory and Critical Care Medicine 2018;197:1.
    1. Volpon LC, Evora PRB, Teixeira GD, et al. Methylene Blue for Refractory Shock in Polytraumatized Patient: A Case Report. J Emerg Med 2018;55(4):553–558.
    1. Cebula B, Musfeldt D. METHYLENE BLUE TO MANAGE MULTIFACTORIAL VASOPLEGIC SHOCK. Critical Care Medicine 2016;44(12):1.
    1. Lee JK, Ing C. Prothrombin Complex Concentrate and Methylene Blue for Treatment of Coagulopathy and Vasoplegia in a Pediatric Heart Transplant Patient. A A Case Rep 2016;6(5):127–129.
    1. Hershman E, Hadash A, Attias O, et al. Methylene blue treatment for resistant shock following renal transplantation. Paediatr Anaesth 2015;25(11):1168–1169.
    1. Rutledge C, Brown B, Benner K, et al. A Novel Use of Methylene Blue in the Pediatric ICU. Pediatrics 2015;136(4):e1030–1034.
    1. Cheng SS, Berman GW, Merritt GR, et al. The response to methylene blue in patients with severe hypotension during liver transplantation. J Clin Anesth 2012;24(4):324–328.
    1. Ali O, Lindley C. Case of methylene blue in severe obstetric sepsis. Bjog-an International Journal of Obstetrics and Gynaecology 2012;119:110–110.
    1. Banille E. Monitoreo Hemodinamico Funcional en Cirugia Cardiovascular pediatrica bajo circulation extracorporea. . REVISTA ARGENTINA DE TERAPIA INTENSIVA 2011;28(4).
    1. López-Suárez O, Pérez-Muñuzuri A, Baña-Souto A, et al. [Methylene blue: usefulness in the treatment of refractory hypotension in premature infants]. Anales de pediatria (Barcelona, Spain : 2003) 2011;74(3):209–210.
    1. Bhalla T, Sawardekar A, Russell H, et al. The role of methylene blue in the pediatric patient with vasoplegic syndrome. World J Pediatr Congenit Heart Surg 2011;2(4):652–655.
    1. Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. Ann Emerg Med 2011;58(6):565–567.
    1. Flynn BC, Sladen RN. The use of methylene blue for vasodilatory shock in a pediatric lung transplant patient. J Cardiothorac Vasc Anesth 2009;23(4):529–530.
    1. Rodrigues JM, Pazin Filho A, Rodrigues AJ, et al. Methylene blue for clinical anaphylaxis treatment: a case report. Sao Paulo Med J 2007;125(1):60–62.
    1. Taylor K, Holtby H. Methylene blue revisited: management of hypotension in a pediatric patient with bacterial endocarditis. J Thorac Cardiovasc Surg 2005;130(2):566.
    1. Pagni S, Austin EH. Use of intravenous methylene blue for the treatment of refractory hypotension after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000;119(6):1297–1298.
    1. Scheffer A, Bahr T, Patel S, et al. METHYLENE BLUE TREATMENT OF VASOPLEGIC SYNDROME IN PEDIATRIC PATIENTS. Critical Care Medicine 2018;46(1):107–107.
    1. Abdelazim R, Salah D, Labib HA, et al. Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized controlled study. Egyptian Journal of Anaesthesia 2016;32(3):269–275.
    1. Hassan GA, Salem YA, Labib HA, et al. Methylene blue for the management of pediatric patients with vasoplegic syndrome. The Egyptian Journal of Cardiothoracic Anesthesia 2014;8(2):66.
    1. Banille E, Paz G, Cacciamano A, et al. Non-invasive monitoring of microcirculation in paediatric patients suffering from septic shock. Cardiology in the Young 2011;1):S86–S87.
    1. Oberpaur B, Donoso A, Clavería C, et al. Azul de metileno en niños con hipotensión refractaria por choque séptico. Revista chilena de pediatría 1997;68(5):205–209.
    1. Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock. Ann Emerg Med 1997;30(2):240.
    1. Driscoll W, Thurin S, Carrion V, et al. Effect of methylene blue on refractory neonatal hypotension. J Pediatr 1996;129(6):904–908.
    1. Rosenbaum HK, Gillman PK. Patient Safety and Methylene Blue-Associated Severe Serotonin Toxicity. A & A case reports 2016;7(1):1.
    1. Sills MR, Zinkham WH. Methylene Blue–Induced Heinz Body Hemolytic Anemia. JAMA Pediatrics 1994;148(3):306–310.
    1. Haque SH, Nossaman BD. Dyed but not dead. Ochsner J 2012;12(2):135–140.
    1. Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med 2006;21(6):359–363.
    1. Juffermans NP, Vervloet MG, Daemen-Gubbels CRG, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010;22(4):275–280.
    1. Buckley MS, Barletta JF, Smithburger PL, et al. Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2019;39(3):382–398.
    1. Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: Impact on hemodynamics and gas exchange. Journal of Critical Care 1998;13(4):164–168.
    1. Wessel DL. Managing low cardiac output syndrome after congenital heart surgery. Crit Care Med 2001;29(10 Suppl):S220–230.
    1. Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003;29(11):1996–2003.
    1. Mazzeffi M, Hammer B, Chen E, et al. Methylene blue for postcardiopulmonary bypass vasoplegic syndrome: A cohort study. Ann Card Anaesth 2017;20(2):178–181.
    1. McCartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia: methylene blue to the rescue! Curr Opin Anaesthesiol 2018;31(1):43–49.
    1. Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 2002;30(10):2271–2277.
    1. Klugman D, Berger JT. Echocardiography and Focused Cardiac Ultrasound. Pediatr Crit Care Med 2016;17(8 Suppl 1):S222–224.
    1. Tissot C, Singh Y, Sekarski N. Echocardiographic Evaluation of Ventricular Function-For the Neonatologist and Pediatric Intensivist. Front Pediatr 2018;6:79.
    1. Radabaugh CL, Ruch-Ross HS, Riley CL, et al. Practice Patterns in Pediatric Critical Care Medicine: Results of a Workforce Survey. Pediatr Crit Care Med 2015;16(8):e308–312.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever